People switching from TDF to TAF experience rising cholesterol levels
Older age and baseline kidney function are the key risk factors for renal dysfunction while taking HIV PrEP
Weight gain after starting HIV treatment may have genetic influences
Far fewer people would get PrEP in the US if generic TDF/FTC is replaced with Descovy (TAF/FTC), cost-effectiveness study finds
PrEP in pregnancy: safe, but many unanswered questions
Truvada, not Descovy, should be the first choice for PrEP, US experts say
Lipid increases after switching from TDF to TAF are reversible when treatment is changed back to TDF
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk
